Volume 76, Pages S50-S99 (August 2009)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 79, Pages S3-S8 (April 2011)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Pleiotropic effects of the non-calcium phosphate binder sevelamer
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Beta blockers in the management of chronic kidney disease
Volume 67, Pages S1-S7 (June 2005)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 79, Issue 9, Pages (May 2011)
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
FGF23 or PTH: which comes first in CKD ?
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Volume 78, Pages S10-S21 (August 2010)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Reassessment of the care of the patient with chronic kidney disease
The risk of hospitalization and modality failure with home dialysis
Volume 63, Pages S88-S90 (June 2003)
Volume 79, Pages S24-S27 (April 2011)
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Volume 65, Issue 5, Pages (May 2004)
Chapter 3: Management of progression and complications of CKD
Need for better diabetes treatment for improved renal outcome
Chapter 2: Methodological approach
Volume 88, Issue 2, Pages (August 2015)
Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study  Wajeh Y. Qunibi, Charles.
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Circulating PTH molecular forms: What we know and what we don't
A new era in phosphate binder therapy: What are the options?
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
Joseph W. Eschbach, John W. Adamson  Kidney International 
The need for reliable serum parathyroid hormone measurements
Volume 66, Pages S25-S32 (September 2004)
The epidemiology of chronic kidney disease
Use of vitamin D in chronic kidney disease patients
Volume 87, Issue 2, Pages (February 2015)
Volume 67, Pages S33-S36 (June 2005)
Edmund G. Lowrie  Kidney International 
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
U-shaped effect of eGFR and mortality
Charles R. Nolan, Wajeh Y. Qunibi  Kidney International 
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism 
Prescribing and monitoring hemodialysis dose
Blood pressure targets in hemodialysis patients
Volume 68, Pages S24-S28 (July 2005)
Volume 74, Pages S88-S93 (December 2008)
Role of vitamin D receptor activators on cardiovascular risk
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Volume 87, Issue 3, Pages (March 2015)
Alternate-day dialysis may be needed for hemodialysis patients
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
Volume 78, Issue 4, Pages (August 2010)
Volume 73, Issue 6, Pages (March 2008)
Volume 56, Issue 3, Pages (September 1999)
Total hip bone mass predicts survival in chronic hemodialysis patients
Volume 72, Issue 2, Pages (July 2007)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
The Danish Renal Biopsy Register
Cardiovascular risk in chronic kidney disease
Recent developments in the management of secondary hyperparathyroidism
Increased fetuin-A levels following treatment with a vitamin D analog
PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.
Volume 74, Issue 10, Pages (November 2008)
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Attributable risk for disorders of mineral metabolism.
Presentation transcript:

Volume 76, Pages S50-S99 (August 2009) Chapter 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium    Kidney International  Volume 76, Pages S50-S99 (August 2009) DOI: 10.1038/ki.2009.192 Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 15 Comparison of PTH levels to underlying bone histology in chronic hemodialysis patients. Intact PTH levels <150 pg/ml presented a 50% sensitivity, an 85% specificity, and an 83% positive predictive value for the diagnosis of low bone turnover (LT). In contrast, iPTH levels>300 pg/ml presented a 69% sensitivity, a 75% specificity, and a 62% positive predictive value for the diagnosis of high bone turnover (HT). iPTH, intact parathyroid hormone; n, number of patients; NL, normal bone turnover. Reprinted with permission from Barreto et al.229 Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 16 Risk of all-cause mortality associated with combinations of baseline serum phosphorus and calcium categories by PTH level. HR, hazard ratio; PTH, parathyroid hormone. Reprinted with permission from Tentori et al.33 Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Kidney International 2009 76, S50-S99DOI: (10.1038/ki.2009.192) Copyright © 2009 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.